NCT06947993 · Novartis Pharmaceuticals
Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
What this study is about
This trial is designed to evaluate multiple compounds in participants with moderate to severe atopic dermatitis (AD).
View original scientific description
This trial is designed to evaluate multiple compounds in participants with moderate to severe atopic dermatitis (AD).
Interventions
DRUG
GHZ339
GHZ339 administered at dose A, B, C and D
DRUG
Placebo
Matching placebo
Primary outcome measures
Change from baseline in the Eczema Area and Severity Index (EASI) score at Week 16
Time frame: Baseline, Week 16
EASI will be used to assess the extend and severity of atopic dermatitis on a scale from 0 to 72 where 72 is worst eczema.
Who can participate
This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.
Inclusion criteria
- of the master protocol:
- Able and willing to sign the informed consent (IC)
- Patients with a diagnosis of AD and onset of disease for at least 1 year
- Moderate to severe AD Key
Exclusion criteria
- of the master protocol:
- Participants with a clinically significant medical condition or infectious disease (specified in sub-protocol)
- Participants with clinically significant abnormal hematology, clinical chemistry, or urine test results or clinically significant abnormal ECG
- Participant with any other active inflammatory skin disease
- Participants with any chronic, uncontrolled medical condition, which would put the participant at increased risk during the study (e.g., uncontrolled: diabetes, hypertension)
- Participants with any clinically unstable disease states that would likely require systemic corticosteroids (e.g., uncontrolled asthma) Additional inclusion and exclusion criteria may apply depending on the intervention specific requirements
Where
- Birmingham, Alabama
- Fort Smith, Arkansas
- Fountain Valley, California
- Los Angeles, California
- Sacramento, California
- Santa Ana, California
- Santa Monica, California
- Washington D.C., District of Columbia
- Miami, Florida
- Atlanta, Georgia
- Macon, Georgia
- Louisville, Kentucky
And 9 more locations — see the full list below.
Related conditions & keywords
Frequently asked questions
What is a clinical trial?
A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.
Is it safe to participate?
Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.
Will I be compensated?
Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.
Will I receive a placebo instead of treatment?
When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.
Can I leave a trial if I change my mind?
Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.
How long does a clinical trial last?
Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.
Data: ClinicalTrials.gov · synced Dec 22, 2025 · Source of record for eligibility and locations